SCHEMBL148930

SCHEMBL148930

NC(CCO)(CCO)CCO

nearest known ligand 0.47

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.47
TSHR P16473 2/20 0.33
ALDH1A1 P00352 1/20 0.33
ARG1 P05089 1/20 0.30
ARG2 P78540 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL1204724 0.96 MEN1 (0.44) MEN1LMNAKMT2ATSHRALDH1A1
Hydrochloric Acid SCHEMBL6660435 0.96 MEN1 (0.44) MEN1LMNAKMT2ATSHRALDH1A1
Bromide SCHEMBL15820403 0.96 MEN1 (0.44) MEN1LMNAKMT2ATSHRALDH1A1
Tromethamine SCHEMBL1933899 0.89 MEN1 (0.67) MEN1LMNAKMT2A
SCHEMBL14481581 0.87 LMNA (0.37) MEN1LMNAKMT2ATSHRALDH1A1
SCHEMBL5056997 0.87 LMNA (0.37) MEN1LMNAKMT2ATSHRALDH1A1
SCHEMBL2351528 0.87 MEN1 (0.37) MEN1LMNAKMT2A
Bicarbonate SCHEMBL8995795 0.87 ARG2 (0.39) MEN1LMNAKMT2AALDH1A1ARG1
SCHEMBL818369 0.87 ALDH1A1 (0.41) MEN1LMNAKMT2ATSHRALDH1A1
SCHEMBL1686256 0.87 LMNA (0.37) MEN1LMNAKMT2ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1022 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4048751-B1 POLISHING COMPOSITION AND METHOD WITH HIGH SELECTIVITY FOR SILICON NITRIDE AND POLYSILICON OVER SILICON OXIDE CMC MAT LLC (US) 2025-03-19 EP claimed
EP-4271719-B1 AQUEOUS COMPOSITION DOW GLOBAL TECHNOLOGIES LLC (US) 2024-11-27 EP claimed
US-20240156808-A1 Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases EDISON ONCOLOGY (US) 2024-05-16 US claimed
EP-3574079-B1 STABLE UNIT DOSE COMPOSITIONS WITH HIGH WATER CONTENT AND STRUCTURED SURFACTANTS HENKEL AG & CO KGAA (DE) 2024-05-01 EP claimed
EP-3481787-B1 HALOGEN-FREE QUATERNARY AMINIES AND USES THEREOF HUNTSMAN PETROCHEMICAL LLC (US) 2024-02-28 EP claimed
US-11905491-B2 Post CMP cleaning compositions ENTEGRIS, INC. (US) 2024-02-20 US claimed
EP-3935119-B1 DRY ELECTRODE ADHESIVE HENKEL AG & CO KGAA (DE) 2024-01-24 EP claimed
US-20240018369-A1 AQUEOUS COMPOSITION DOW GLOBAL TECHNOLOGIES LLC 2024-01-18 US claimed
EP-4034605-B1 POLISHING COMPOSITIONS AND METHODS OF USE THEREOF FUJIFILM ELECTRONIC MAT USA INC (US) 2024-01-17 EP claimed
EP-4045226-B1 POLISHING COMPOSITIONS AND METHODS OF USE THEREOF FUJIFILM ELECTRONIC MAT USA INC (US) 2024-01-03 EP claimed
EP-0763132-B1 ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY ISOLAB INC (US) 2001-01-24 EP claimed
US-5719035-A MEASURING FLUORESCENT ENZYME PRODUCT ISOLAB, INC. (US) 1998-02-17 US claimed
EP-0763132-A4 ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY ISOLAB INC (US) 1997-06-18 EP claimed
EP-0763132-A1 ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY ISOLAB, INC. (US) 1997-03-19 EP claimed
US-5538857-A FLUORESCENCE ISOLAB, INC. (US) 1996-07-23 US claimed
WO-1995033072-A1 ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY ISOLAB, INC. (US) 1995-12-07 WO claimed
EP-0621772-A1 HAIR FIXER. WELLA AG (DE) 1994-11-02 EP claimed
WO-1994012147-A1 HAIR FIXER WELLA AKTIENGESELLSCHAFT (DE) 1994-06-09 WO claimed
EP-0375225-A2 Palladium alloy plating process AT&T Corp. (US) 1990-06-27 EP claimed
US-4911798-A Palladium alloy plating process AT&T BELL LABORATORIES (US) 1990-03-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156808-A1 Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases TOP2A, TOP2B, TOP1 MEN1 601/4885LMNA 1413/4885KMT2A 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.